Epitranscriptomics of Ischemic Heart Disease—The IHD-EPITRAN Study Design and Objectives

Show full item record



Permalink

http://hdl.handle.net/10138/333699

Citation

Sikorski , V , Karjalainen , P , Blokhina , D , Oksaharju , K , Khan , J , Katayama , S , Rajala , H , Suihko , S , Tuohinen , S S , Teittinen , K , Nummi , A , Nykänen , A , Eskin , A , Stark , C , Biancari , F , Kiss , J , Simpanen , J , Ropponen , J O , Lemström , K , Savinainen , K , Lalowski , M , Kaarne , M , Jormalainen , M , Elomaa , O , Koivisto , P , Raivio , P , Bäckström , P , Dahlbacka , S , Syrjälä , S , Vainikka , T , Vähäsilta , T , Tuncbag , N , Karelson , M , Mervaala , E , Juvonen , T , Laine , M , Laurikka , J , Vento , A & Kankuri , E 2021 , ' Epitranscriptomics of Ischemic Heart Disease—The IHD-EPITRAN Study Design and Objectives ' , International Journal of Molecular Sciences , vol. 22 , no. 12 , 6630 . https://doi.org/10.3390/ijms22126630

Title: Epitranscriptomics of Ischemic Heart Disease—The IHD-EPITRAN Study Design and Objectives
Author: Sikorski, Vilbert; Karjalainen, Pasi; Blokhina, Daria; Oksaharju, Kati; Khan, Jahangir; Katayama, Shintaro; Rajala, Helena; Suihko, Satu; Tuohinen, Suvi Sirkku; Teittinen, Kari; Nummi, Annu; Nykänen, Antti; Eskin, Arda; Stark, Christoffer; Biancari, Fausto; Kiss, Jan; Simpanen, Jarmo; Ropponen, Jussi O; Lemström, Karl; Savinainen, Kimmo; Lalowski, Maciej; Kaarne, Markku; Jormalainen, Mikko; Elomaa, Outi; Koivisto, Pertti; Raivio, Peter; Bäckström, Pia; Dahlbacka, Sebastian; Syrjälä, Simo; Vainikka, Tiina; Vähäsilta, Tommi; Tuncbag, Nurcan; Karelson, Mati; Mervaala, Eero; Juvonen, Tatu; Laine, Mika; Laurikka, Jari; Vento, Antti; Kankuri, Esko
Contributor: University of Helsinki, Medicum
University of Helsinki, Kardiologian yksikkö
University of Helsinki, Department of Pharmacology
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, Clinicum
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, Clinicum
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUSLAB
University of Helsinki, Department of Biochemistry and Developmental Biology
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUSLAB
University of Helsinki, Kardiologian yksikkö
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, III kirurgian klinikka
University of Helsinki, Sydän ja rintaelinkirurgia
University of Helsinki, Eero Mervaala / Principal Investigator
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, Esko Markus Kankuri / Principal Investigator
Date: 2021-06-21
Language: eng
Number of pages: 28
Belongs to series: International Journal of Molecular Sciences
ISSN: 1422-0067
URI: http://hdl.handle.net/10138/333699
Abstract: Epitranscriptomic modifications in RNA can dramatically alter the way our genetic code is deciphered. Cells utilize these modifications not only to maintain physiological processes, but also to respond to extracellular cues and various stressors. Most often, adenosine residues in RNA are targeted, and result in modifications including methylation and deamination. Such modified residues as N-6-methyl-adenosine (m6A) and inosine, respectively, have been associated with cardiovascular diseases, and contribute to disease pathologies. The Ischemic Heart Disease Epitranscriptomics and Biomarkers (IHD-EPITRAN) study aims to provide a more comprehensive understanding to their nature and role in cardiovascular pathology. The study hypothesis is that pathological features of IHD are mirrored in the blood epitranscriptome. The IHD-EPITRAN study focuses on m6A and A-to-I modifications of RNA. Patients are recruited from four cohorts: (I) patients with IHD and myocardial infarction undergoing urgent revascularization; (II) patients with stable IHD undergoing coronary artery bypass grafting; (III) controls without coronary obstructions undergoing valve replacement due to aortic stenosis and (IV) controls with healthy coronaries verified by computed tomography. The abundance and distribution of m6A and A-to-I modifications in blood RNA are charted by quantitative and qualitative methods. Selected other modified nucleosides as well as IHD candidate protein and metabolic biomarkers are measured for reference. The results of the IHD-EPITRAN study can be expected to enable identification of epitranscriptomic IHD biomarker candidates and potential drug targets.
Subject: 3121 General medicine, internal medicine and other clinical medicine
biomarkers
ischemic heart disease
epitranscriptomics
N6-methyladenosine
m6A
adenosine-to-inosine
A-to-I
RNA modifications
biomarkers
epitranscriptomics
ischemic heart disease
N-6-methyladenosine
adenosine-to-inosine
A-to-I
RNA M(6)A METHYLATION
SINGLE-NUCLEOTIDE-RESOLUTION
BRAIN NATRIURETIC PEPTIDE
STEM-CELL PROLIFERATION
PRE-MESSENGER-RNA
PLATELET MICROPARTICLES
CARDIOVASCULAR-DISEASE
SOLUBLE SUPPRESSION
PROGNOSTIC VALUE
ATHEROSCLEROTIC PLAQUES
1182 Biochemistry, cell and molecular biology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
ijms_22_06630_v2.pdf 2.780Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record